Else Kröner Research Schools for Physicians

Funding for a Successful Professional Career as Physician Performing Research: The Else Kröner-Fresenius-Stiftung foundation wants to support the medical faculties and university hospitals in Germany within the framework of group research programmes.
Research at Internal Medicine II Clinic, Uniklinik Freiburg
Research at Internal Medicine II Clinic, Uniklinik Freiburg
(© Uniklinik Freiburg)

This programme allows young, extremely talented physicians in scientific fields to have an optimal environment for fostering their research work; to enable entry to a successful professional career as clinician scientist.

The Else Kröner Research Schools for Physicians are an innovative tool in the German funding landscape and are geared to research-intensive university hospitals. The scholars can focus fully on their research project for one to two years and work on a joint subject area within a scientifically excellent research group. An accompanying curriculum also creates an extensive knowledge base and establishes contacts with international experts.

The maximum funding volume per group research programme amounts to €1.3 million for three years, with the option of a second funding period.

Please always take note of our current calls for applications/proposals for this line of funding. You can find them in the menu “Current Topics” under Call for Proposals.
 

Submitting the Paper of the Month:
We invite all project managers, fellowship recipients and members of graduate study programs to submit their publications that have emerged from funding as Paper of the Month. You can find more information here. You can find an overview of the Paper of the Month here. 
 

Portrait Dr. Alexander Lehmann
Dr. Alexander Lehmann
Scientific Funding: Graduate and Research Schools and International Research Prize
a.lehmann@ekfs.de
+49 (6172) 8975-25
Related links
Research Schools for Physicians: Special Topic „Rare Diseases“
Since 2019 the EKFS has funded two research programs on the topic of rare diseases. The call for proposals and selection of the research programs occurred in close cooperation with the foundation Eva Luise und Horst Köhler Stiftung. Three locations are involved in each of the two programs.

Overview of current Else Kröner Research Schools for Physicians:

2021

Gene, Mechanism, Therapy: A Network for Precision Medicine of Genetic Neurological Diseases | PRECISE.net (Tübingen)

University of Tübingen

Spokespersons: Prof. Dr. Matthis Synofzik, PD Dr. Rebecca Schüle (deputy speaker), Prof. Dr. Holger Lerche (deputy speaker)

Here you can get further information.

You can find the project presentation here.

Immunooncology and local interventions, IOLIN (Munich)

LMU Klinikum

Spokespersons: Prof. Dr. Sebastian Kobold, Prof. Dr. Kirsten Lauber (deputy speaker), Prof. Dr. Dr. Michael von Bergwelt (deputy speaker)

Granted in 2021 for 3 years.

Here you can get further information.

You can find the project presentation here.

 

iPRIME – Clinician Scientist (Hamburg)

University Medical Center Hamburg-Eppendorf (UKE)

Spokespersons: Prof. Dr. Tobias B. Huber, Prof. Dr. Ulf Panzer

Granted in 2021 for 3 years.

You can find the project presentation here.

2019

TWINSIGHT – Systems Immunology and High-throughput Technology (Würzburg)

Spokespersons: Prof. Dr. Bastian Schilling, Prof. Dr. Alma Zernecke-Madsen

Granted in 2019 for 3 years.

Here you can get further information.

Development and establishment of predictive models for the realization of personalized tumor therapy (Ulm)

Universitätsklinikum Ulm

Spokespersons: Prof. Dr. Thomas Seufferlein, Prof. Dr. Alexander Kleger, PD Dr. Jan Krönke

Granted in 2019 for 3 years.

Here you can get further information.

Neurooncology: Resistance in brain tumours (Heidelberg)

Universitätsklinikum Heidelberg

Spokespersons: Prof. Dr. Wolfgang Wick, Prof. Dr. Stefan Pfister, Prof. Dr. Martin Bendszus

Granted in 2019 for 3 years.

Here you can get further information.

 

2018

The three colleges selected for funding in 2018 successfully applied for a second funding period in 2022 for three additional years.

Gut-brain axis: relevance for inflammation and neurodegeneration (Kiel)

Universitätsklinikum Schleswig-Holstein    

Spokespersons: Prof. Dr. Daniela Berg, Prof. Dr. Thorsten Bartsch, Prof. Dr. Stefan Schreiber

Here you can find further information.

The role of the diseased hepatic microenvironment for tumor initiation and progression in liver cancer (Mainz)

Universitätsmedizin Mainz

Spokespersons: Prof. Dr. Peter R. Galle, Prof. Dr. Julia Weinmann-Menke

Here you can find further information.

You can find the project presentation here.

TITUS - The First Thousand Days of Life (Hannover)

Medizinische Hochschule Hannover

Spokespersons: Prof. Dr. Gesine Hansen, Prof. Dr. Reinhold Förster

Here you can find further information.

2016

Phosphoproteom-Dynamics (Dresden)

Universitätsklinikum Dresden

Spokespersons: Prof. Dr. Ali El-Armouche, Prof. Dr. Martin Bornhäuser

Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.

Here you can find further information.

You can find the project presentation here.

Interdisciplinary Translational Immuno-Oncology (Regensburg)

Universitätsklinikum Regensburg

Spokespersons: Prof. Dr. Peter J. Oefner, Prof. Dr. Wolfgang Herr, Prof. Dr. med. Philipp Beckhove

Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.

You can find the project presentation here.

Here you can find further information.

 

Immunological Causes and Therapies of Cancer (Freiburg)

Universitätsklinikum Freiburg

Spokespersons: Prof. Dr. Heike Pahl, Prof. Dr. Robert Thimme

Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.

Here you can find further information.

 

Targeting therapy-induced dynamic alterations within the cancer genome (Köln)

Universitätsklinikum Köln

Spokespersons: Prof. Dr. Matthias Fischer, Prof. Dr. Christiane J. Bruns, Dr. Ron Jachimowicz

Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.

Here you can find further information.

 

2015

Therapeutic resistance of solid tumours (Tübingen)

Universitätsklinikum Tübingen

Spokeswoman: Prof. Dr. Dr. Ghazaleh Tabatabai

Granted in 2016 for three years, one-time extension for a further 3 years following a successful review in 2019.

Immunotherapy for the Treatment of Cancer (Munich)

Klinikum der LMU München

Spokeswoman: Prof. Dr. Marion Subklewe

Granted in 2016 for three years, one-time extension for a further 3 years following a successful review in 2019.

Here you can find further information.

You can find the project presentation here.

 

Translational Psychiatry (Munich)

Klinikum der LMU München

Spokepersons Prof. Dr. Peter Falkai, Prof. Dr. Dr. Elisabeth Binder

Granted in 2016 for three years, one-time extension for a further 3 years following a successful review in 2019.

Here you can find further information.

You can find the project presentation here.

 

Aging and disease: translational analysis of therapeutic interventions (Jena)

Universitätsklinikum Jena

Spokepersons: Prof. Dr. Otto W. Witte, Prof. Dr. Uta Dahmen, Prof. Dr. Regine Heller

Granted in 2016 for three years, one-time extension for a further 3 years following a successful review in 2019.

Here you can find further information.

You can find the project presentation here.

2013

Molecular Therapy and Prediction in Gastrointestinal Malignoma (Göttingen)

Universitätsmedizin Göttingen

Spokepersons: Prof. Dr. Matthias Dobbelstein, Prof. Dr. med. Volker Ellenrieder, Prof. Dr. B. Michael Ghadimi

Granted in 2014 for three years, one-time extension for a further 3 years following a successful review in 2018.

Here you can find further information.

You can find the project presentation here.

Targeted Therapies (Frankfurt)

Universitätsklinikum Frankfurt

Spokepersons: Prof. Dr. med. Simone Fulda, Prof. Dr. Christian Brandts

Granted in 2014 for three years, one-time extension for a further 3 years following a successful review in 2018.

Here you can find further information.

You can find the project presentation here.

The significance of the inflammatory microenvironment for the development of cancer (Magdeburg)

Universitätsklinikum Magdeburg    

Spokepersons: Prof. Dr. med. Thomas Fischer, Prof. Dr. med. Thomas Tüting

Granted in 2014 for three yearst, one-time extension for a further 3 years following a successful review in 2018.

Here you can find further information.

You can find the project presentation here.

2012

Renal impairment as a complication of systemic diseases (Freiburg)

Universitätsklinikum Freiburg

Spokepersons: Prof. Dr. Gerd Walz

Granted in 2013 for three years, one-time extension for a further 3 years following a successful review in 2018.

Here you can find further information.

You can find the project presentation here.

Microbial triggers in disease development (Munich)

Klinikum rechts der Isar, TU München

Spokepersons: Prof. Dr. Ulrike Protzer, Prof. Dr. Tilo Biedermann

Granted in 2013 for 3 years, one-time extension for a further 3 years following a successful review in 2016.

Here you can find further information.

 

Rare diseases of the immune system (Munich)

Klinikum der LMU München

Spokeperson: Prof. Dr. Christoph Klein

Granted in 2013 for three years, one-time extension following a successful review in 2016.

Here you can find further information.

 

2010

Jörg C. Kalff, Bonn University Hospital

Innate immunity and chronic organ dysfunction.

Granted in 2011 for 3 years, one-time extension for a further 3 years following a successful review in 2014.

Here you can get further information.

Stephan Stilgenbauer, Ulm University Hospital

Stem cells, aging and malignant transformation. From experimental model to clinical application.

Granted in 2011 for 3 years, one-time extension for a further 3 years following a successful review in 2014.

Here you can get further information.

Andreas Beilhack, Würzburg University Hospital

Interdisciplinary translational immunology.

Granted in 2011 for 3 years, one-time extension for a further 3 years following a successful review in 2014.